Enhanced with market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports deliver more actionable and strategically valuable research.
Typhoid Vi Polysaccharide Vaccine Market Expansion From $7.92 Billion In 2026 To $15.5 Billion In 2030
The market for typhoid vi polysaccharide vaccines experienced notable growth, projected to expand from $6.71 billion in 2025 to $7.92 billion in 2026, reflecting a robust compound annual growth rate of 18.1%. Factors contributing to this expansion during the preceding period included the integration of the vaccine into national immunization programs, heightened public consciousness regarding typhoid prevention, the accessibility of polysaccharide vaccine options, the momentum generated by public vaccination initiatives, and the supportive involvement of international health organizations.
The market for typhoid vi polysaccharide vaccines is poised for significant expansion over the coming years, with projections indicating a substantial climb to $15.51 billion by 2030. This upward trajectory is underpinned by a robust compound annual growth rate (CAGR) of 18.3%, driven primarily by intensified efforts towards mass immunization campaigns in areas where typhoid is prevalent. Furthermore, increased funding directed towards bolstering vaccine production capabilities, the broadening scope of vaccination initiatives for adults, a heightened awareness of the importance of immunizations for travelers, and the greater utilization of advanced vaccine preservation methods are all contributing factors to this projected growth. Key developments anticipated during this forecast period encompass an escalation in government-sponsored vaccination schemes, a surge in the need for comprehensive childhood immunization coverage, a more pronounced dedication to proactive health measures, the proliferation of collaborative public-private partnerships for vaccine distribution, and a concerted effort to optimize the cold chain logistics essential for vaccine efficacy.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=8313&type=smp
Typhoid Vi Polysaccharide Vaccine Market Expansion Supported By Key Demand Factors
The increasing incidence of typhoid is anticipated to stimulate the expansion of the typhoid Vi polysaccharide vaccine market in the future. This bacterial infection, Salmonella Typhi, poses a potentially lethal threat and is predominantly transmitted via contaminated ingestibles or liquids. Factors contributing to the surge in typhoid cases include inadequate sanitation infrastructure, compromised water supplies, rapid urban expansion, and heightened exposure to tainted food and beverages. To combat this, the typhoid Vi polysaccharide vaccine market offers a vital immunization option for individuals aged two years and above, both adults and children, thereby conferring protection against Salmonella enterica serovar Typhi and alleviating the impact of typhoid fever in areas where it is prevalent. For illustrative purposes, data from the UK Health Security Agency, released in August 2024, indicated a rise in laboratory-confirmed symptomatic enteric fever cases across England, Wales, and Northern Ireland, with Salmonella Typhi accounting for 313 instances, Salmonella Paratyphi A for 135, and Salmonella Paratyphi B for 18. Consequently, the escalating prevalence of typhoid is a key driver for the growth of the typhoid Vi polysaccharide vaccine market.
The proliferation of immunization initiatives is poised to accelerate the development of the typhoid Vi polysaccharide vaccine market. These campaigns are defined by methodologies designed for efficient vaccine delivery to extensive populations at national or regional scales. The impetus behind the expansion of such campaigns stems from an intensified public health emphasis on preventing typhoid in regions with a high disease burden and the critical necessity to curb antibiotic resistance through broad vaccination efforts. Such widespread immunization campaigns bolster the typhoid Vi polysaccharide vaccine by enhancing its visibility, ensuring easier access, and increasing uptake rates, which collectively contribute to a reduction in both the occurrence and spread of typhoid fever. As an example, the UK Health Security Agency, a governmental body in the United Kingdom, reported in June 2023 that a total of 3,502,566 children, spanning Reception to Year 9, received vaccinations through the school-aged program during the 2022–2023 period. Therefore, the expanding scope of immunization campaigns serves as a significant driver for the growth of the typhoid Vi polysaccharide vaccine market.
Typhoid Vi Polysaccharide Vaccine Market Segment Outlook: Which Categories Are Expanding The Fastest?
The typhoid vi polysaccharide vaccine market covered in this report is segmented –
1) By Type: Child, Adult
2) By Route Of Administration: Oral, Parenteral
3) By Application: Government Institution, Private Sector, Other Applications
Subsegments:
1) By Child: Pediatric Formulations, Age-Specific Dosages
2) By Adult: Standard Adult Formulations, High-Risk Population Formulations
Typhoid Vi Polysaccharide Vaccine Market Growth Trends Influencing Competitive Dynamics
Key players within the typhoid Vi polysaccharide vaccine sector are actively working to solidify their standing by making strategic financial commitments, including the establishment of funding collaborations for advanced vaccine delivery systems, with the objective of spurring innovation and broadening the scope of worldwide vaccination efforts. These collaborations for next-generation vaccine delivery platforms involve joint investment endeavors designed to cultivate more effective typhoid vaccination methodologies, specifically those that are administered without needles, remain stable at various temperatures, and are straightforward to deploy, thereby improving accessibility, coverage, and adherence in areas with limited resources. An illustrative example is the August 2023 arrangement where SK Bioscience, a biotechnology firm headquartered in South Korea, in conjunction with Vaxxas, an Australian biotechnology enterprise known for its expertise in needle-free vaccine delivery, obtained AUD 0.0054 billion (equivalent to USD 0.00367 billion) in financial backing from Wellcome, a charitable foundation based in the UK, to advance the development of a typhoid conjugate vaccine intended for delivery via a needle-free high-density microarray patch (HD-MAP). This groundbreaking development incorporates a micro-projection patch that obviates the necessity for conventional needles, offers thermal stability crucial for deployment in regions with underdeveloped infrastructure, and presents the possibility of a simplified, painless administration process, all aimed at enhancing the worldwide adoption of typhoid immunization.
Typhoid Vi Polysaccharide Vaccine Market Key Companies And Competitive Benchmarking
Major companies operating in the typhoid vi polysaccharide vaccine market are Sanofi S.A., Merck & Co. Inc., PT Bio Farma, Bharat Biotech International Limited, Bio-Med Pvt. Ltd., Hualan Biological Engineering Inc., Indian Immunologicals Limited, Serum Institute of India Limited, Biological E Limited, Panacea Biotec Limited, Zydus Lifesciences Limited, Beijing Minhai Biotechnology Co. Ltd., Lanzhou Institute of Biological Products Co. Ltd., Chengdu Institute of Biological Products Co. Ltd., Wuhan Institute of Biological Products Co. Ltd., Eubiologics Co. Ltd., Incepta Vaccine Limited, GC Pharma, KM Biologics Inc., Bharat Immunologicals and Biologicals Corporation Limited, Sinovac Biotech Ltd., Bio Farma Indonesia
Access The Complete Typhoid Vi Polysaccharide Vaccine Market Report:
Typhoid Vi Polysaccharide Vaccine Market Regional Analysis And Leading Geography
Asia-Pacificwas the largest region in the typhoid Vi polysaccharide vaccine market share in 2025. The regions covered in the typhoid vi polysaccharide vaccine market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
